GW Pharma (GWPH) Posts Q1 Loss of 9c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq leads Wall St higher as Nvidia eases AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil prices rise as investors weigh lack of progress in Middle East negotiations
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
May 5, 2016 7:02 AM EDT- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome -- Initial LGS Phase 3 pivotal data expected in June -- Conference call today at 9:00 a.m. EDT, 2:00 p.m. BST -
LONDON, May 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH) (AIM: GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year... More
The Cannabis Market Reaches New Heights
May 4, 2016 2:35 PM EDTNEW YORK, May 4, 2016 /PRNewswire/ --
It is a rare opportunity when a market that is potentially worth hundreds of billions of dollars is virtually untouched by large companies. While the number of states where the growth and sales of Cannabis products remains limited, the majority of the population in the United States approves the end of federal marijuana prohibition nationwide. For now, in states where cannabis is a legitimate and legal product, sales are through the roof. Â
A recent report by New Frontier and ArcView Market Research has revealed some very impressive numbers. Sales of... More
